Wegovy manufacturer Novo Nordisk reports quarterly profit in line with expectations, while adjusting full-year guidance.

On Wednesday, Novo Nordisk reported earnings for the third quarter that were roughly in line with expectations, and the company also revised its full-year growth forecast for 2024.

The Danish pharmaceutical giant reported a net profit of 27.3 billion Danish kroner ($3.92 billion) in the third quarter, exceeding the LSEG aggregate estimate of 26.95 billion Danish kroner.

The earnings before tax and income (EBIT) for the company were 33.8 billion Danish kroner, slightly above the LSEG forecast of 33.51 billion Danish kroner.

The company revised its sales growth forecast for the full year 2024 to a range of 23% to 27%, down from the previous range of 22% to 28% at constant exchange rates.

Despite facing intensified competition, Novo Nordisk has received encouraging developments in the weight-loss market in recent months.

The U.S. Food and Drug Administration announced that all doses of Wegovy are now available in the U.S., after previously stating that the lowest dose was in short supply. This news signaled that Novo Nordisk's efforts to increase the supply of Wegovy and diabetes drug Ozempic are successful.

In October, a study found that Ozempic may decrease the likelihood of developing Alzheimer's disease, potentially delaying or preventing the condition.

— CNBC's Annika Kim Constantino contributed to this story